RecruitingNCT07180264
Trastuzumab Deruxtecan in Advanced Breast Cancer
Trastuzumab Deruxtecan in Patients With Advanced Breast Cancer: a Real-world Study
Sponsor
Wenjin Yin
Enrollment
118 participants
Start Date
Aug 28, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
To evaluate the efficacy and safety of trastuzumab deruxtecan in advanced breast cancer patients.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Aged ≥18 and older
- Breast cancer patients meeting current guideline recommendations and planning to receive trastuzumab deruxtecan
- ECOG 0-1
Exclusion Criteria1
- During pregnancy and lactation
Interventions
DRUGTrastuzumab deruxtecan
Trastuzumab deruxtecan is a combination of the targeted cancer drug trastuzumab (also known as Herceptin) and a chemotherapy drug called deruxtecan or DXd.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07180264
Related Trials
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892139 locations
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
NCT066493311 location
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
NCT0699384410 locations
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
NCT0699702921 locations
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
NCT042224132 locations